Sarepta Therapeutics | SRPT - Ebitda


Sarepta Therapeutics reported $126.42M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Capricor Therapeutics USD -24.58M 17.26M Mar/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novavax USD -117.12M 55.66M Sep/2024
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025